The U.S. Food and Drug Administration (FDA) has accepted the premarket tobacco product application (PMTA) submitted on Sept. 2, 2020, by Bantam Vape, a supplier of e-liquids based in North Carolina, USA.
The filing letter signifies completion of FDA’s preliminary review of Bantam’s PMTA and the progression of its application into the formal substantive review phase. During this phase, FDA will conduct an in-depth evaluation of the scientific studies and other materials submitted in conjunction with Bantam’s application.
“Bantam is pleased its PMTA has been formally filed and will be entering the scientific review phase of this process,” said Bantam spokesperson Anthony Dillon in a statement.
“Bantam looks forward to engaging with FDA as it reviews the submission and scientific research provided in support of the filing. Bantam’s goal has always been to provide consumers with high-quality, science-based e-liquid products that can be enjoyed for years to come. News of the filing brings Bantam one step closer to reaching that goal.”